Literature DB >> 32794460

Tuberculosis and COVID-19: An overlapping situation during pandemic.

Rabia Can Sarınoğlu1, Uluhan Sili2, Emel Eryuksel3, Sehnaz Olgun Yildizeli4, Cagatay Cimsit5, Aysegul Karahasan Yagci6.   

Abstract

INTRODUCTION: The novel coronavirus severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible for the coronavirus disease 2019 (COVID-19). First COVID-19 case was detected in March, 10, 2020 in Turkey and as of May, 18, 2020 148,067 cases have been identified and 4096 citizens have died. Tuberculosis (TB) is a worldwide public health concern, incidence of tuberculosis (per 100,000 people) in Turkey was reported at 14, 1 in 2018. During pandemic COVID-19 was the main concern in every clinic and as we discuss here overlapping respiratory diseases may result in delaying of the diagnosis and treatment.
METHODOLOGY: There were 4605 respiratory samples examined between March 23 and May 18 for COVID-19 and 185 samples for Mycobacterium tuberculosis in our laboratory. The Xpert Ultra assay was performed for the diagnosis of pulmonary tuberculosis; SARS-CoV-2 RNA was determined by real-time PCR (RT-PCR) analysis in combined nasopharyngeal and deep oropharyngeal swabs of suspected cases of COVID-19.
RESULTS: Both of SARS-CoV-2 and M. tuberculosis tests were requested on the clinical and radiological grounds in 30 patients. Here we discussed 2 patients who were both COVID-19 and TB positive. One patient already diagnosed with tuberculosis become COVID-19 positive during hospitalization and another patient suspected and treated for COVID-19 received the final diagnosis of pulmonary TB and Human Immunodeficiency Virus infection.
CONCLUSIONS: We want to emphasize that while considering COVID-19 primarily during these pandemic days, we should not forget one of the "great imitators", tuberculosis within differential diagnoses. Copyright (c) 2020 Rabia Can Sarınoğlu, Uluhan Sili, Emel Eryuksel, Sehnaz Olgun Yildizeli, Cagatay Cimsit, Aysegul Karahasan Yagci.

Entities:  

Keywords:  COVID-19; Mycobacterium tuberculosis; PCR; SARS-CoV-2; Tuberculosis

Mesh:

Substances:

Year:  2020        PMID: 32794460     DOI: 10.3855/jidc.13152

Source DB:  PubMed          Journal:  J Infect Dev Ctries        ISSN: 1972-2680            Impact factor:   0.968


  12 in total

1.  Risk of SARS-CoV-2 Infection Among People Living With HIV in Wuhan, China.

Authors:  Mengmeng Wu; Fangzhao Ming; Songjie Wu; Yanbin Liu; Xiaoxia Zhang; Wei Guo; Gifty Marley; Weiming Tang; Ke Liang
Journal:  Front Public Health       Date:  2022-04-29

2.  Worldwide prevalence of microbial agents' coinfection among COVID-19 patients: A comprehensive updated systematic review and meta-analysis.

Authors:  Reza Pakzad; Pooneh Malekifar; Zainab Shateri; Milad Zandi; Sara Akhavan Rezayat; Maral Soleymani; Mohammad Reza Karimi; Seyed Esmaeil Ahmadi; Ramin Shahbahrami; Iraj Pakzad; Fatemeh Abdi; Abbas Farahani; Saber Soltani; Mina Mobini Kesheh; Parastoo Hosseini
Journal:  J Clin Lab Anal       Date:  2021-12-01       Impact factor: 2.352

Review 3.  Clinical Characteristics, Diagnosis, Treatment, and Mortality Rate of TB/COVID-19 Coinfectetd Patients: A Systematic Review.

Authors:  Maryam Koupaei; Adel Naimi; Narges Moafi; Paria Mohammadi; Faezeh Sadat Tabatabaei; Soroosh Ghazizadeh; Mohsen Heidary; Saeed Khoshnood
Journal:  Front Med (Lausanne)       Date:  2021-12-01

4.  Tuberculosis amidst COVID-19 in Pakistan: a massive threat of overlapping crises for the fragile healthcare systems.

Authors:  Hashir Ali Awan; Abdul Moiz Sahito; Mahnoor Sukaina; Govinda Khatri; Summaiya Waheed; Fatima Sohail; Mohammad Mehedi Hasan
Journal:  Epidemiol Infect       Date:  2022-02-22       Impact factor: 2.451

Review 5.  Mycobacterium tuberculosis and SARS-CoV-2 Coinfections: A Review.

Authors:  Narjess Bostanghadiri; Faramarz Masjedian Jazi; Shabnam Razavi; Lanfranco Fattorini; Davood Darban-Sarokhalil
Journal:  Front Microbiol       Date:  2022-02-03       Impact factor: 5.640

6.  Global prevalence, treatment and outcome of tuberculosis and COVID-19 coinfection: a systematic review and meta-analysis (from November 2019 to March 2021).

Authors:  Quan Wang; Shasha Guo; Xiaolin Wei; Quanfang Dong; Ning Xu; Hui Li; Jie Zhao; Qiang Sun
Journal:  BMJ Open       Date:  2022-06-20       Impact factor: 3.006

Review 7.  Clinical Features and Treatment Outcome of Coronavirus and Tuberculosis Co-Infected Patients: A Systematic Review of Case Reports.

Authors:  Hilina Mollalign; Dawit Chala; Dereje Beyene
Journal:  Infect Drug Resist       Date:  2022-07-27       Impact factor: 4.177

8.  A university-clustered tuberculosis outbreak during the COVID-19 pandemic in eastern China.

Authors:  Jizhou Wu; Limei Zhu; Jiaxi Yu; Qiao Liu; Xiaoyan Ding; Peng Lu; Yunliang Wu; Jiansheng Sun; Leonardo Martinez; Wei Lu; Jianming Wang
Journal:  Front Public Health       Date:  2022-08-23

9.  Bacterial coinfection among coronavirus disease 2019 patient groups: an updated systematic review and meta-analysis.

Authors:  S Soltani; S Faramarzi; M Zandi; R Shahbahrami; A Jafarpour; S Akhavan Rezayat; I Pakzad; F Abdi; P Malekifar; R Pakzad
Journal:  New Microbes New Infect       Date:  2021-07-01

Review 10.  Mesenchymal Stem Cells and Tuberculosis: Clinical Challenges and Opportunities.

Authors:  Xueying Zhang; Qi Xie; Ziyu Ye; Yanyun Li; Zhengping Che; Mingyuan Huang; Jincheng Zeng
Journal:  Front Immunol       Date:  2021-07-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.